Find the Right Market Report

Search thousands of industry reports, market insights, and research studies in one place.

Not sure where to start? Try one of these:
Explore healthcare market intelligence and industry insights
Towards Healthcare

Latent Tuberculosis Infection Detection Companies, Corporate Growth and Development Strategy

Date : 24 March 2026

Latest Updates of Key Players in the Latent Tuberculosis Infection Detection Market

Latent Tuberculosis Infection Detection Market Companies are QIAGEN, BIOMÉRIEUX, Oxford Immunotec, SD Biosensor, INC., Wantai BioPharm, Lionex GmbH

All your Latent Tuberculosis Infection Detection Market intelligence, organized and ready; click to access

Company Headquarters Latest Update
QIAGEN Germany QIAGEN announced a positive court conclusion, strengthening a significant patent for the QuantiFERON-TB testing technology.
BIOMÉRIEUX France bioMérieux is massively involved in both latent tuberculosis infection (LTBI) identification and the rapid characterization of drug-resistant tuberculosis.
Oxford Immunotec United Kingdom Oxford Immunotec continues to hold a significant position in the detection of latent tuberculosis infection (LTBI).
SD Biosensor, INC. South Korea In August 2025, SD Biosensor Inc. announced that its latent tuberculosis (TB) diagnostic product, STANDARD E TB-Feron ELISA, had been officially included in the World Health Organization (WHO) recommendation list for TB diagnostics.
Wantai BioPharm China Wantai's TB-IGRA CLIA is designed for application as an aid in the diagnosis of TB infection, including both latent TB infection and Tuberculosis disease.
Lionex GmbH Germany In November 2025, LIONEX recently launched a novel IGRA diagnostic test called LIOFeron®TB/LTBI for LTBI.

Supply Chain Analysis

R&D:

  • Research and development (R&D) for latent tuberculosis infection detection includes shifting beyond traditional processes such as the Tuberculin Skin Test (TST) to more accurate, molecular, and biomarker-driven technologies.
  • Key Players: F. Hoffmann-La Roche and Serum Institute of India Pvt. Ltd.

Manufacturing Processes:

  • Manufacturing processes for latent tuberculosis infection detection focus on two main immunological strategies, such as the Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs). 
  • Key Players: bioMérieux and SD Biosensor

Patient Services:

  • Patient services for latent tuberculosis infection detection mainly focus on identifying patients at risk of developing active tuberculosis and initiating preventative treatment to break the chain of detection.
  • Key Players: Qiagen and Oxford Immunotec

Market Growth

The global latent tuberculosis infection detection market size was estimated at USD 2.05 billion in 2025 and is predicted to increase from USD 2.17 billion in 2026 to approximately USD 3.65 billion by 2035, expanding at a CAGR of 5.94% from 2026 to 2035.

Latent Tuberculosis Infection Detection Market Size is USD 2.17 Billion in 2026.

Recent Developments in the Latent Tuberculosis Infection Detection Market

  • In 2025, Prime Minister Modi announced a plan to eliminate tuberculosis in India by 2025. With more patients dying of TB in India than anywhere else in the world, this is a big step forward and hopefully will inspire other countries to take action.
  • In November 2025, Serum Institute of India (SIIPL) Pvt. Ltd., part of Cyrus Poonawalla Group, in partnership with its UK subsidiary Serum Life Sciences Ltd, is pleased to announce that the Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom, has granted Marketing Authorisation for SIILTIBCY, a new tuberculosis (TB) skin test.

Ready to make better
healthcare business decisions?

Speak with a healthcare analyst about your research, consulting, or platform needs.

Talk to an Analyst Contact Sales